MHRA joins Consortium of Regulators - without EU
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has joined the Australia-Canada-Singapore-Switzerland (ACSS) Consortium.
The ACSS consortium was formed in 2007 and comprised the national regulatory authorities of Australia, Canada, Singapore and Switzerland. Now, after MHRA has joined, the group's name was changed to 'Access'. The MHRA will commence work-sharing applications with Access partners from 1 January 2021. The members aim to promote greater regulatory collaboration and alignment of regulatory requirements. In this context he Access Consortium explores opportunities for information and work-sharing in areas including:
- generic medicines registration
- assessment reports for new prescription medicines
- information sharing and investigations into post-market medicine safety
- alignment of IT systems for information sharing
- development of technical guidelines.
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years